Gene Therapy for Blinding Disease Enters Pivotal Trial

DURHAM, N.C. – April 20, 2026 – In a major step forward for genetic medicine, Atsena Therapeutics announced today that it has received the recommendation to proceed with the final, pivotal stage of a clinical trial for its groundbreaking gene therapy, ATSN-201. The decision, made by an independent Data Monitoring Committee (DMC), clears the path for the company to begin enrolling patients in the Phase 3 portion of its LIGHTHOUSE study, which aims to treat X-linked retinoschisis (XLRS), a rare genetic disease that causes progressive vision loss and blindness in boys and young men.

This milestone brings what could be the first-ever approved treatment for XLRS one step closer to reality, offering significant hope to the approximately 30,000 affected males in the U.S. and Europe who currently have no therapeutic options to halt or reverse the disease's devastating effects.

"We are excited that the DMC has recommended that we proceed with the pivotal Part C cohort," said Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics. "This recommendation reflects the strength of the safety and efficacy data we have accumulated to date and brings us one step closer to delivering what we believe will be the first approved therapy for patients with XLRS."

An End to the Waiting Game?

XLRS is a debilitating inherited retinal disease caused by mutations in the RS1 gene. This gene is responsible for producing retinoschisin, a protein that acts like cellular glue, holding the delicate layers of the retina together. Without functional retinoschisin, these layers split apart—a condition known as schisis—leading to the formation of tiny cysts and tears that damage photoreceptor cells and impair vision.

Typically diagnosed in early childhood, the disease manifests as poor visual acuity that cannot be corrected with glasses. While vision may stabilize for a period, it often declines sharply again in middle age, leading to legal blindness. Until now, patient care has been limited to managing complications like retinal detachments or providing low-vision aids. The lack of a disease-modifying treatment has left a profound unmet need within the patient community.

The advancement of ATSN-201 into its pivotal trial phase signals a potential paradigm shift. Early data from the Phase 1/2 portion of the LIGHTHOUSE trial has been encouraging, with the majority of treated patients showing improvements in retinal structure—specifically, the closure of schisis cavities in the fovea, the center of the retina responsible for sharp vision. Patients also demonstrated meaningful gains in visual function, offering the first clinical evidence that a gene therapy could effectively combat the disease.

Innovative Technology to Overcome a Surgical Hurdle

At the heart of Atsena's promising therapy is a novel piece of technology: the AAV.SPR vector. Traditional ocular gene therapies are delivered via a subretinal injection, which creates a small blister, or bleb, to deliver the therapeutic gene. However, the genetic payload typically remains confined to this small area. To treat the entire central retina, this would traditionally require a risky injection directly into the fragile fovea, risking surgical damage to the very cells the therapy aims to save.

ATSN-201's AAV.SPR capsid is engineered to overcome this fundamental challenge. The 'SPR' stands for 'spreading,' and it does just that. The vector is designed to spread laterally beyond the initial injection site. This allows surgeons to administer the therapy in a safer, peripheral area of the retina while still enabling the therapeutic gene to transduce a wide swath of photoreceptor cells across the crucial central retina.

This innovative delivery system not only minimizes surgical risk but also maximizes the potential therapeutic benefit. Preclinical studies in non-human primates confirmed that AAV.SPR efficiently delivers its genetic payload to the fovea without the need for direct, dangerous foveal detachment, a significant advancement in the field of ocular gene therapy.

A Clear Path Toward Approval

The structure of the LIGHTHOUSE trial itself is designed for speed and efficiency. By combining Phases 1, 2, and 3 into a single, continuous study, Atsena has streamlined the development process in agreement with the U.S. Food and Drug Administration (FDA). This approach is expected to shorten the clinical timeline by more than a year compared to running separate trials.

Part C, the pivotal Phase 3 portion, will now enroll 76 patients across leading clinical sites in North America and Europe. The study will include a treatment arm and a control arm, with patients in the control group being observed for 12 months before having the option to receive ATSN-201. Screening for this final cohort is set to begin this month, with enrollment expected to be complete by the end of the first quarter of 2027.

The potential of ATSN-201 has already been recognized by regulatory bodies. It has received a host of designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug status. These designations are reserved for promising therapies addressing serious unmet needs and are designed to expedite the review and approval process. If the data from Part C is positive, Atsena expects to file for a Biologics License Application (BLA) in 2028, marking the final step before potential market availability.

Building a Pipeline for Vision

The progress with ATSN-201 is the leading edge of a broader strategy for Atsena Therapeutics. Founded by pioneers in ocular gene therapy and backed by over $238 million in financing, the company is leveraging its proprietary technologies to build a robust pipeline of treatments for inherited retinal diseases.

Beyond XLRS, Atsena is advancing a gene therapy for Usher Syndrome Type 1B and Stargardt Disease. Furthermore, its collaboration with Nippon Shinyaku on ATSN-101 for Leber congenital amaurosis type 1 (LCA1) is also moving toward a global pivotal trial. This multi-program approach, anchored by innovative capsid technology and a strong financial foundation, positions Atsena as a formidable force in the fight against genetic blindness. For the thousands of families affected by XLRS, the start of this pivotal trial is more than just a corporate milestone; it is a beacon of tangible hope on the horizon.